Antios Therapeutics is a biopharmaceutical company developing innovative therapies for viral diseases.
Antios Therapeutics has raised $75.0M in total funding. The most recent round was Series B. The last funding was announced in November 2021.
Antios Therapeutics's investors include RA Capital Management, Lumira Ventures, Fonds de solidarité FTQ, Adage Capital Management, Delos Capital.
Antios Therapeutics is headquartered in Atlanta, United States.
Antios Therapeutics is a biopharmaceutical company developing innovative therapies for viral diseases.
Antios Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Antios Therapeutics — Funding & Investors." VCBacked, November 3, 2021, https://www.vcbacked.co/company/antios-therapeutics. Accessed November 15, 2026.
VCBacked. (2021). Antios Therapeutics — Funding & Investors. Retrieved November 15, 2026, from https://www.vcbacked.co/company/antios-therapeutics
{{cite web |title=Antios Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/antios-therapeutics |website=VCBacked |access-date=November 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Antios Therapeutics? Request a listing update